Avalo Therapeutics, Inc. · NASDAQ:AVTX
Varki Paul sold 75,063 Avalo Therapeutics, Inc. shares (Form 4)
Traded May 6, 2026 · Filed May 7, 2026
On May 6, 2026, Varki Paul (Chief Legal Officer) sold 75,063 Avalo Therapeutics, Inc. shares at an average US$20.17 for US$1.51M under a trading plan, leaving 3,634 shares. Filed May 7, 2026 (Form 4).
- Sold
- 75,063 shares
- Price
- US$20.17 average (US$18.91 to US$23.71)
- Value
- US$1.51M
- Holding after
- 3,634 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Legal Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| May 6, 2026 | Common Stock | Option exercise | 62,500 | US$13.43 | 66,134 | Direct |
| May 6, 2026 | Common Stock | Option exercise | 12,563 | US$8.04 | 78,697 | Direct |
| May 6, 2026 | Common Stock | Sale | 37,375 | US$18.91 | 41,322 | Direct |
| May 6, 2026 | Common Stock | Sale | 5,196 | US$19.78 | 36,126 | Direct |
| May 6, 2026 | Common Stock | Sale | 22,839 | US$21.22 | 13,287 | Direct |
| May 6, 2026 | Common Stock | Sale | 9,253 | US$22.70 | 4,034 | Direct |
| May 6, 2026 | Common Stock | Sale | 400 | US$23.71 | 3,634 | Direct |
Source
Related
- Avalo Therapeutics, Inc.
- Varki Paul
- Avalo Therapeutics, Inc. shareholders
- Form 4 · Varki Paul · Jun 12, 2026
- Form 4 · Varki Paul · May 26, 2026
- Form 4 · Sullivan Christopher Ryan · Sep 18, 2026
- Form 4 · Sullivan Christopher Ryan · Sep 11, 2026
- Form 4 · Doyle Mittie · Sep 1, 2026
- Form 4 · Sullivan Christopher Ryan · Aug 19, 2026
- Form 4 · Doyle Mittie · Aug 19, 2026